Access Pharmaceuticl (ACCP) 0.3000 $ACCP
Global Male Infertility Market (Techniques and Geography) Report 2014-2020
M2 - Wed Aug 27, 2:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n33x3/global_male) has announced the addition of the "Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020" report to their offering. The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 4.9% during 2013-2020 Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels. The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient. The repeated failures would compel most patients to discontinue the treatment. The other limitation is the social taboo. Out of 32-40% infertile men, only 15% of the men opt for the treatment for infertility due to the embarrassment, guilt, etc. The opportunity driving the market is medical tourism and increase in awareness about male infertility. The treatment for male infertility is expensive; however, the cost of the treatment is expected to decrease with the advancement in treatment technologies. The other factor that may drag the prices lower would be the patients' expectations for cost effective treatments. These factors would drive the male infertility market. MARKET BY TECHNIQUES - DNA Fragmentation Technique - Oxidative Stress Analysis - Microscopic Examination - Sperm Penetration Assay - Sperm Agglutination - Computer Assisted Semen Analysis - Others Companies Mentioned - Access Pharmaceuticals - Andrology Solutions. - ASKA Pharmaceutical Co. Ltd - Cordex Pharma - Halotech DNA SL - Intas Pharmaceuticals Ltd. - Merck Serono - Pantarhei Bioscience B - SCSA diagnostics - ZydusCadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4n...lobal_male
Access Pharmaceuticals wins patent for MuGard and ProctiGard in Japan, strengthening its intellectual property protection in additional global market
M2 - Fri Aug 15, 7:44AM CDT
Biopharmaceutical company Access Pharmaceuticals (Other OTC:ACCP) disclosed on Thursday the receipt of a patent from the Japan Patent Office for MuGard and ProctiGard.
Access Pharmaceuticals Awarded Japan Patent For MuGard And ProctiGard
PR Newswire - Thu Aug 14, 8:16AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Japan Patent Office that a patent for MuGard and ProctiGard has been granted. The patent covers a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders.
Norgine In-Licenses MUGARD(R) for Oral Mucositis in Europe
PR Newswire Europe - Thu Aug 07, 7:01AM CDT
LONDON, August 7, 2014 /PRNewswire/ --
Access Pharmaceuticals Announces European License Agreement With Norgine
PR Newswire - Thu Aug 07, 7:00AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with Norgine B.V., a leading independent European specialty pharmaceutical company, for the commercialization of MuGard in Europe. Under the terms of the license agreement, Access will receive up to $10 million in milestone payments and an escalating double digit royalty on the net sales of the oral mucositis product, MuGard, in the licensed territories. Norgine will develop, manufacture, and commercialize MuGard in the European Union, Switzerland, Norway, Iceland and Lichtenstein. Norgine anticipates launching MuGard in 2015.
Access Pharmaceuticals Featured On OncLive.com
PR Newswire - Wed Jul 30, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a developer of new products for oncology supportive care, announced that its novel product for oral mucositis, MuGard®, has been featured in an article on OncLive.com titled, "Study Finds Mouth Rinse Alleviates Oral Mucositis Symptoms in Head and Neck Cancers." Dr. Steve Sonis, a leading expert in oral mucositis, provides insight on the growing demand seen in the oncology community for evidence-based strategies for the debilitating anticancer regimen side effect.
Access Pharmaceuticals wins US FDA's marketing clearance for ProctiGard for oncology side effects, rectal mucositis and radiation proctitis
M2 - Wed Jul 23, 7:22AM CDT
Oncology care company Access Pharmaceuticals (Other OTC:ACCP) disclosed on Tuesday the receipt of the 510(K) marketing clearance from the US Food and Drug Administration (FDA) for its novel treatment for symptomatic management of rectal mucositis, ProctiGard.
Access Pharmaceuticals Receives 510(K) FDA Marketing Clearance For ProctiGard(TM)
PR Newswire - Tue Jul 22, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a developer of new products for oncology supportive care, announced today that it has received 510(K) marketing clearance from the U.S. Food and Drug Administration (FDA) for ProctiGard(TM), its novel treatment for symptomatic management of rectal mucositis. The Company indicated its development of ProctiGard(TM) is a direct response to dialogue with the oncology community that is looking for better, more effective treatment options for rectal mucositis and radiation proctitis, a debilitating oncology side effect. Access believes that ProctiGard is a first-in-class treatment option that addresses a significant unmet medical need. Access currently holds global commercialization rights for ProctiGard.
Access Pharmaceuticals wins patent for MuGard in Hong Kong, further strengthening its global patent portfolio position
M2 - Wed Jul 09, 5:48AM CDT
Biopharmaceutical company Access Pharmaceuticals (Other OTC:ACCP) reported on Tuesday the receipt of the patent (HK1126134) from the Hong Kong Patent Office for MuGard.
Access Pharmaceuticals Awarded Hong Kong Patent For MuGard
PR Newswire - Tue Jul 08, 9:56AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Hong Kong Patent Office that a patent for MuGard(TM) has been granted. The patent (HK1126134) protects a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders.
Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020
M2 - Fri Jun 27, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/995rbn/global_male) has announced the addition of the "Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020" report to their offering. The report "Male Infertility Market (Techniques and Geography) - Global Industry Analysis, Size, Growth Trends, Share, Opportunities and Forecast 2012 - 2020," revealed that the global male infertility market was valued at $216 million in 2013, and it is estimated to reach $301.5 million by 2020, registering a CAGR of 5% during 2014-2020. Infertility in male is characterized by various infertility related problems such as low sperm count, presence of low motile sperm or azoospermia. The various causes of male infertility include stress, consumption of alcohol or drugs, smoking, obesity, environmental toxins, etc. These factors also act as driving factors of the male infertility market. When an individual is diagnosed with infertility, the person undergoes immense stress, embarrassment and guilt, which would further intensify the infertility problem. This is a major limitation of this market. The opportunity for the growth of this market is the increase in awareness levels among men and rising trend in medical tourism. Key Topics Covered: CHAPTER 1 INTRODUCTION CHAPTER 2 EXECUTIVE SUMMARY CHAPTER 3 MARKET SIZING CHAPTER 4 CONSIDERATIONS AND PROCESS - MALE INFERTILITY & IVF TREATMENT CHAPTER 5 SEMEN ANALYSIS TECHNIQUES - MARKET SIZE AND ANALYSIS CHAPTER 6 GLOBAL MALE INFERTILITY MARKET BY GEOGRAPHY CHAPTER 7 COMPANY PROFILES Companies Mentioned: - Access Pharmaceuticals - Andrology Solutions. - ASKA Pharmaceutical Co. Ltd - Cordex Pharma - Halotech DNA SL - Intas Pharmaceuticals Ltd. - Merck Serono - Pantarhei Bioscience B - SCSA diagnostics - ZydusCadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/99...lobal_male
Nanoparticle Drug Delivery Market & Clinical Pipeline Insight Report 2014
M2 - Tue Jun 17, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vppwdk/nanoparticle_drug) has announced the addition of the "Nanoparticle Drug Delivery Market & Clinical Pipeline Insight" report to their offering. Drug delivery technologies currently occupy a significant position in the pharmaceutical industry. It has become so important that the mode of delivery of drugs has come to define the efficiency and marketability of those drugs. The pharmaceutical industry is witnessing a shift in the focus of the stakeholders towards newer systems of drug delivery in order to achieve efficient and safe transportation of novel products and formulations. There have been many products which have been derived from new delivery systems and are currently attracting the attention of different companies. It has been recognized that the introduction of a new drug delivery system would bring along a potential chance for an existing drug candidate molecule. The field of nanotechnology is considered to be an exciting area which offers the potential for developing drug delivery systems using nanoparticles, with dimension range of 1-100 nm. These nanoparticles tend to have the ability to deliver an adequate range of molecules to different areas of the body. Additionally, these nanoparticles also posses the capability to deliver the molecules for a comparatively longer duration of time as compared to other routes. The major objectives of a drug delivery system based on nanoparticles, are size of particles, surface properties and discharge of drugs or the active ingredients in order to attain the maximum level of efficiency. The combination of nanotechnology along with medicine has resulted in potential concepts and ideas for the pharma industry which is set to introduce momentous innovations in the fight against different diseases. The two concepts of therapeutic nanocarriers - liposomes and albumin nanoparticles are gaining prominence rapidly and would soon become well-established in the market across the globe. The need of the hour currently is to obtain a deeper understanding of the biodistribution of nanoparticles, which is influenced mainly by their ability to negotiate biological barriers. Nanoparticle Drug Delivery Market & Clinical Pipeline Insight- Report Highlights: - Nanoparticle Drug Delivery Market Overview - Nanoparticle Drug Delivery Mechanism - Clinical Pipeline by Phase & Target Indications - Drug Profiles in Report: 190 - Majority of Nanoparticle Drug in Preclinical Phase: 70 - Marketed Nanoparticle Drugs: 12 - Suspended & Discontinued Drug Profiles Key Topics Covered: 1. Introduction to Nanoparticle Technology for Drug Delivery 2. Nanoparticle Drug Delivery Mechanism 3. Application of Nanotechnology for Drug Delivery 4. Nanoparticle Drug Delivery Market Overview 5. Nanoparticle Drug Delivery Market Dynamics 6. Nanoparticle Drug Delivery Clinical Pipeline by Phase, Country & Indication 7. Marketed Nanoparticle Drug 8. Suspended & Discontinued Nanoparticle Drug Profiles 9. Competitive Landscape - Abraxis BioScience, - Access Pharmaceuticals, - Alnylam Pharmaceuticals, - Arrowhead Research, - BIND Biosciences, - NanoCarrier, - Nanobiotix, - Nippon Kayaku, - Samyang - iCeutica, For more information visit http://www.researchandmarkets.com/research/vp...ticle_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals Provides Strategic Update On Mucoadhesive Polymer Hydrogel Technology
PR Newswire - Tue Apr 01, 7:16AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and includes the ability to act as a delivery system for a variety of active agents, including drugs.
Access Pharmaceuticals Cobraxane(TM) Offers Enhanced Tumor Growth Inhibition In Tumor Models
PR Newswire - Wed Mar 26, 7:14AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and expand applications, and is actively seeking development partners globally. Access compared single doses of Cobraxane(TM), its proprietary nanoparticle formulation of commercially available protein-bound paclitaxel, with Abraxane® in a standard mouse tumor model. At a dose of Cobraxane(TM) which was half that of the maximum tolerated dose (MTD) of the standard paclitaxel particles, Cobraxane(TM) demonstrated slightly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Cobraxane(TM), injected at the same dose as the MTD dose of standard paclitaxel particles, provided significantly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Tumor shrinkage was observed at the higher dose of Cobraxane(TM). Access believes the preclinical data observed is a strong indicator of potential clinical and commercial value of Cobraxane(TM).
Access Pharmaceuticals Advances Development of ProctiGard(TM) for Radiation Proctitis
PR Newswire - Fri Mar 21, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has advanced development of a new proprietary product, called ProctiGard(TM), for the treatment of radiation proctitis. Radiation proctitis ("RP"
is a significant unmet medical need, with no well-established standard of care. It is estimated that there are in excess of 250,000 new cases of prostate, cervical, rectal, testicular, bladder and endometrial cancer diagnosed each year. Approximately 50% of these patients require radiation therapy, and roughly 75% of patients undergoing pelvic irradiation experience radiation proctitis. Access is actively seeking marketing partners globally for ProctiGard(TM).
Access Pharmaceuticals Announces MuGard License Agreement With Hanmi Pharmaceutical In Korea
PR Newswire - Tue Mar 11, 7:52AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) today announced that it had entered into an exclusive license agreement with HANMI PHARMACEUTICAL CO., LTD. (KSE: 128940) related to MuGard commercialization in South Korea. Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients in the US alone developing the condition each year.
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals Announces Publication Of MuGard Clinical Data In Cancer Journal
PR Newswire - Tue Feb 18, 7:30AM CST
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced the online early publication of the final results of its post-approval marketing study of MuGard® in Cancer, the journal of the American Cancer Society and one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral Mucositis Symptoms in Patients Being Treated With Chemoradiation Therapy for Cancers of the Head and Neck," is available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. The publication discusses data on Access' post-marketing clinical trial that evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck.
Access Pharmaceuticals Awarded Second European Patent for MuGard
PR Newswire Europe - Thu Sep 12, 7:31AM CDT
-- Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets
Global Male Infertility Market (Techniques and Geography) Report 2014-2020
M2 - Wed Aug 27, 2:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n33x3/global_male) has announced the addition of the "Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020" report to their offering. The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 4.9% during 2013-2020 Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels. The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient. The repeated failures would compel most patients to discontinue the treatment. The other limitation is the social taboo. Out of 32-40% infertile men, only 15% of the men opt for the treatment for infertility due to the embarrassment, guilt, etc. The opportunity driving the market is medical tourism and increase in awareness about male infertility. The treatment for male infertility is expensive; however, the cost of the treatment is expected to decrease with the advancement in treatment technologies. The other factor that may drag the prices lower would be the patients' expectations for cost effective treatments. These factors would drive the male infertility market. MARKET BY TECHNIQUES - DNA Fragmentation Technique - Oxidative Stress Analysis - Microscopic Examination - Sperm Penetration Assay - Sperm Agglutination - Computer Assisted Semen Analysis - Others Companies Mentioned - Access Pharmaceuticals - Andrology Solutions. - ASKA Pharmaceutical Co. Ltd - Cordex Pharma - Halotech DNA SL - Intas Pharmaceuticals Ltd. - Merck Serono - Pantarhei Bioscience B - SCSA diagnostics - ZydusCadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4n...lobal_male
Access Pharmaceuticals wins patent for MuGard and ProctiGard in Japan, strengthening its intellectual property protection in additional global market
M2 - Fri Aug 15, 7:44AM CDT
Biopharmaceutical company Access Pharmaceuticals (Other OTC:ACCP) disclosed on Thursday the receipt of a patent from the Japan Patent Office for MuGard and ProctiGard.
Access Pharmaceuticals Awarded Japan Patent For MuGard And ProctiGard
PR Newswire - Thu Aug 14, 8:16AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Japan Patent Office that a patent for MuGard and ProctiGard has been granted. The patent covers a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders.
Norgine In-Licenses MUGARD(R) for Oral Mucositis in Europe
PR Newswire Europe - Thu Aug 07, 7:01AM CDT
LONDON, August 7, 2014 /PRNewswire/ --
Access Pharmaceuticals Announces European License Agreement With Norgine
PR Newswire - Thu Aug 07, 7:00AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with Norgine B.V., a leading independent European specialty pharmaceutical company, for the commercialization of MuGard in Europe. Under the terms of the license agreement, Access will receive up to $10 million in milestone payments and an escalating double digit royalty on the net sales of the oral mucositis product, MuGard, in the licensed territories. Norgine will develop, manufacture, and commercialize MuGard in the European Union, Switzerland, Norway, Iceland and Lichtenstein. Norgine anticipates launching MuGard in 2015.
Access Pharmaceuticals Featured On OncLive.com
PR Newswire - Wed Jul 30, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a developer of new products for oncology supportive care, announced that its novel product for oral mucositis, MuGard®, has been featured in an article on OncLive.com titled, "Study Finds Mouth Rinse Alleviates Oral Mucositis Symptoms in Head and Neck Cancers." Dr. Steve Sonis, a leading expert in oral mucositis, provides insight on the growing demand seen in the oncology community for evidence-based strategies for the debilitating anticancer regimen side effect.
Access Pharmaceuticals wins US FDA's marketing clearance for ProctiGard for oncology side effects, rectal mucositis and radiation proctitis
M2 - Wed Jul 23, 7:22AM CDT
Oncology care company Access Pharmaceuticals (Other OTC:ACCP) disclosed on Tuesday the receipt of the 510(K) marketing clearance from the US Food and Drug Administration (FDA) for its novel treatment for symptomatic management of rectal mucositis, ProctiGard.
Access Pharmaceuticals Receives 510(K) FDA Marketing Clearance For ProctiGard(TM)
PR Newswire - Tue Jul 22, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a developer of new products for oncology supportive care, announced today that it has received 510(K) marketing clearance from the U.S. Food and Drug Administration (FDA) for ProctiGard(TM), its novel treatment for symptomatic management of rectal mucositis. The Company indicated its development of ProctiGard(TM) is a direct response to dialogue with the oncology community that is looking for better, more effective treatment options for rectal mucositis and radiation proctitis, a debilitating oncology side effect. Access believes that ProctiGard is a first-in-class treatment option that addresses a significant unmet medical need. Access currently holds global commercialization rights for ProctiGard.
Access Pharmaceuticals wins patent for MuGard in Hong Kong, further strengthening its global patent portfolio position
M2 - Wed Jul 09, 5:48AM CDT
Biopharmaceutical company Access Pharmaceuticals (Other OTC:ACCP) reported on Tuesday the receipt of the patent (HK1126134) from the Hong Kong Patent Office for MuGard.
Access Pharmaceuticals Awarded Hong Kong Patent For MuGard
PR Newswire - Tue Jul 08, 9:56AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Hong Kong Patent Office that a patent for MuGard(TM) has been granted. The patent (HK1126134) protects a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders.
Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020
M2 - Fri Jun 27, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/995rbn/global_male) has announced the addition of the "Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020" report to their offering. The report "Male Infertility Market (Techniques and Geography) - Global Industry Analysis, Size, Growth Trends, Share, Opportunities and Forecast 2012 - 2020," revealed that the global male infertility market was valued at $216 million in 2013, and it is estimated to reach $301.5 million by 2020, registering a CAGR of 5% during 2014-2020. Infertility in male is characterized by various infertility related problems such as low sperm count, presence of low motile sperm or azoospermia. The various causes of male infertility include stress, consumption of alcohol or drugs, smoking, obesity, environmental toxins, etc. These factors also act as driving factors of the male infertility market. When an individual is diagnosed with infertility, the person undergoes immense stress, embarrassment and guilt, which would further intensify the infertility problem. This is a major limitation of this market. The opportunity for the growth of this market is the increase in awareness levels among men and rising trend in medical tourism. Key Topics Covered: CHAPTER 1 INTRODUCTION CHAPTER 2 EXECUTIVE SUMMARY CHAPTER 3 MARKET SIZING CHAPTER 4 CONSIDERATIONS AND PROCESS - MALE INFERTILITY & IVF TREATMENT CHAPTER 5 SEMEN ANALYSIS TECHNIQUES - MARKET SIZE AND ANALYSIS CHAPTER 6 GLOBAL MALE INFERTILITY MARKET BY GEOGRAPHY CHAPTER 7 COMPANY PROFILES Companies Mentioned: - Access Pharmaceuticals - Andrology Solutions. - ASKA Pharmaceutical Co. Ltd - Cordex Pharma - Halotech DNA SL - Intas Pharmaceuticals Ltd. - Merck Serono - Pantarhei Bioscience B - SCSA diagnostics - ZydusCadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/99...lobal_male
Nanoparticle Drug Delivery Market & Clinical Pipeline Insight Report 2014
M2 - Tue Jun 17, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vppwdk/nanoparticle_drug) has announced the addition of the "Nanoparticle Drug Delivery Market & Clinical Pipeline Insight" report to their offering. Drug delivery technologies currently occupy a significant position in the pharmaceutical industry. It has become so important that the mode of delivery of drugs has come to define the efficiency and marketability of those drugs. The pharmaceutical industry is witnessing a shift in the focus of the stakeholders towards newer systems of drug delivery in order to achieve efficient and safe transportation of novel products and formulations. There have been many products which have been derived from new delivery systems and are currently attracting the attention of different companies. It has been recognized that the introduction of a new drug delivery system would bring along a potential chance for an existing drug candidate molecule. The field of nanotechnology is considered to be an exciting area which offers the potential for developing drug delivery systems using nanoparticles, with dimension range of 1-100 nm. These nanoparticles tend to have the ability to deliver an adequate range of molecules to different areas of the body. Additionally, these nanoparticles also posses the capability to deliver the molecules for a comparatively longer duration of time as compared to other routes. The major objectives of a drug delivery system based on nanoparticles, are size of particles, surface properties and discharge of drugs or the active ingredients in order to attain the maximum level of efficiency. The combination of nanotechnology along with medicine has resulted in potential concepts and ideas for the pharma industry which is set to introduce momentous innovations in the fight against different diseases. The two concepts of therapeutic nanocarriers - liposomes and albumin nanoparticles are gaining prominence rapidly and would soon become well-established in the market across the globe. The need of the hour currently is to obtain a deeper understanding of the biodistribution of nanoparticles, which is influenced mainly by their ability to negotiate biological barriers. Nanoparticle Drug Delivery Market & Clinical Pipeline Insight- Report Highlights: - Nanoparticle Drug Delivery Market Overview - Nanoparticle Drug Delivery Mechanism - Clinical Pipeline by Phase & Target Indications - Drug Profiles in Report: 190 - Majority of Nanoparticle Drug in Preclinical Phase: 70 - Marketed Nanoparticle Drugs: 12 - Suspended & Discontinued Drug Profiles Key Topics Covered: 1. Introduction to Nanoparticle Technology for Drug Delivery 2. Nanoparticle Drug Delivery Mechanism 3. Application of Nanotechnology for Drug Delivery 4. Nanoparticle Drug Delivery Market Overview 5. Nanoparticle Drug Delivery Market Dynamics 6. Nanoparticle Drug Delivery Clinical Pipeline by Phase, Country & Indication 7. Marketed Nanoparticle Drug 8. Suspended & Discontinued Nanoparticle Drug Profiles 9. Competitive Landscape - Abraxis BioScience, - Access Pharmaceuticals, - Alnylam Pharmaceuticals, - Arrowhead Research, - BIND Biosciences, - NanoCarrier, - Nanobiotix, - Nippon Kayaku, - Samyang - iCeutica, For more information visit http://www.researchandmarkets.com/research/vp...ticle_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals Provides Strategic Update On Mucoadhesive Polymer Hydrogel Technology
PR Newswire - Tue Apr 01, 7:16AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and includes the ability to act as a delivery system for a variety of active agents, including drugs.
Access Pharmaceuticals Cobraxane(TM) Offers Enhanced Tumor Growth Inhibition In Tumor Models
PR Newswire - Wed Mar 26, 7:14AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and expand applications, and is actively seeking development partners globally. Access compared single doses of Cobraxane(TM), its proprietary nanoparticle formulation of commercially available protein-bound paclitaxel, with Abraxane® in a standard mouse tumor model. At a dose of Cobraxane(TM) which was half that of the maximum tolerated dose (MTD) of the standard paclitaxel particles, Cobraxane(TM) demonstrated slightly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Cobraxane(TM), injected at the same dose as the MTD dose of standard paclitaxel particles, provided significantly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Tumor shrinkage was observed at the higher dose of Cobraxane(TM). Access believes the preclinical data observed is a strong indicator of potential clinical and commercial value of Cobraxane(TM).
Access Pharmaceuticals Advances Development of ProctiGard(TM) for Radiation Proctitis
PR Newswire - Fri Mar 21, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has advanced development of a new proprietary product, called ProctiGard(TM), for the treatment of radiation proctitis. Radiation proctitis ("RP"
is a significant unmet medical need, with no well-established standard of care. It is estimated that there are in excess of 250,000 new cases of prostate, cervical, rectal, testicular, bladder and endometrial cancer diagnosed each year. Approximately 50% of these patients require radiation therapy, and roughly 75% of patients undergoing pelvic irradiation experience radiation proctitis. Access is actively seeking marketing partners globally for ProctiGard(TM). Access Pharmaceuticals Announces MuGard License Agreement With Hanmi Pharmaceutical In Korea
PR Newswire - Tue Mar 11, 7:52AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) today announced that it had entered into an exclusive license agreement with HANMI PHARMACEUTICAL CO., LTD. (KSE: 128940) related to MuGard commercialization in South Korea. Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients in the US alone developing the condition each year.
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals Announces Publication Of MuGard Clinical Data In Cancer Journal
PR Newswire - Tue Feb 18, 7:30AM CST
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced the online early publication of the final results of its post-approval marketing study of MuGard® in Cancer, the journal of the American Cancer Society and one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral Mucositis Symptoms in Patients Being Treated With Chemoradiation Therapy for Cancers of the Head and Neck," is available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. The publication discusses data on Access' post-marketing clinical trial that evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck.
Access Pharmaceuticals Awarded Second European Patent for MuGard
PR Newswire Europe - Thu Sep 12, 7:31AM CDT
-- Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets
